10.1093/brain/awx024 13 AsensiM.SastreJ.PallardoF
Hruby and Mac Hadley (University of Arizona, USA) in 19871989 Original development program Competitive Technologies Palatin Technologies , later spun off into PT-141 (bremelanotide) Target: non-selective agonist of MC1R, MC3R, MC4R, MC5R (more potent than -MSH, longer half-life) Standard experimental dose in human tanning studies: 0.025 mg/kg subcutaneously (Dorr 1996) In Dorr 1996 (n=10): increase in skin melanin density measured by colorimetry by ~25 % after a 10-day course Main adverse effects in the preclinical literature: nausea, flushing, hyperpigmentation (including atypical nevi), priapism Approximately 100+ publications in PubMed
Int J Pept Res Ther 27:22912301 Wang M-D, Hou D-Y, Lv G-T, Li R-X, Hu X-J, Wang Z-J, Zhang N-Y, Yi L, Xu W-H et al (2021b) Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency
A highly elevated LPR is associated with more unfavorable outcomes several months after injury and increased mortality in several clinical groups [26, 28, 33, 42]
10.1016/j.fct.2017.07.018 134 OzaM